Evidence map›Paper›PMID 39012808›Full record

ArticleAnnals of clinical and translational neurology2024

Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug-resistant epilepsy.

Wenzheng Xiong, Tianrong Yeo, Jeanne Tan May May, Tor Demmers, Bryan Ceronie, Archana Ramesh, Ronan N McGinty, Sophia Michael, Emma Torzillo, Arjune Sen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wenzheng XiongDepartment of Chemistry, University of Oxford, Oxford, UK.ORCID 0000-0001-5713-7305
Tianrong YeoDepartment of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, UK.
Jeanne Tan May MayDepartment of Neurology, National Neuroscience Institute, Singapore, Singapore.
Tor DemmersDepartment of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, UK.
Bryan CeronieNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Archana RameshNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Ronan N McGintyNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Sophia MichaelNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Emma TorzilloNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Arjune SenNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Daniel C AnthonyDepartment of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, UK.
Sarosh R IraniNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID 0000-0002-7667-9748
Fay ProbertDepartment of Chemistry, University of Oxford, Oxford, UK.

Funding

British Medical AssociationDorothy Hodgkin Early Career Fellowship in ChemistryEpilepsy Research UKIrish Clinical Academic Training ProgrammeMedical Research Council MC_PC_20002Medical Research Council MR/V007173/1MRF MR/V007173/1National Medical Research Council MOH-TA20nov-002NIHR Oxford Biomedical Research Centrethe Fulbright UK-US CommissionUCB PharmaWellcome Trust Fellowship 104079/Z/14/Z
6 · The paper itself

Abstract

objectiveDifferentiating forms of autoimmune encephalitis (AE) from other causes of seizures helps expedite immunotherapies in AE patients and informs studies regarding their contrasting pathophysiology. We aimed to investigate whether and how Nuclear Magnetic Resonance (NMR)-based metabolomics could differentiate AE from drug-resistant epilepsy (DRE), and stratify AE subtypes.

methodsThis study recruited 238 patients: 162 with DRE and 76 AE, including 27 with contactin-associated protein-like 2 (CASPR2), 29 with leucine-rich glioma inactivated 1 (LGI1) and 20 with N-methyl-d-aspartate receptor (NMDAR) antibodies. Plasma samples across the groups were analyzed using NMR spectroscopy and compared with multivariate statistical techniques, such as orthogonal partial least squares discriminant analysis (OPLS-DA).

resultsThe OPLS-DA model successfully distinguished AE from DRE patients with a high predictive accuracy of 87.0 ± 3.1% (87.9 ± 3.4% sensitivity and 86.3 ± 3.6% specificity). Further, pairwise OPLS-DA models were able to stratify the three AE subtypes. Plasma metabolomic signatures of AE included decreased high-density lipoprotein (HDL, -(CH

interpretationThis study presents the first non-antibody-based biomarker for differentiating DRE, AE and AE subtypes. These metabolomics signatures underscore the potential relevance of lipid metabolism and glucose regulation in these neurological disorders, offering a promising adjunct to facilitate the diagnosis and therapeutics.

Indexed as

Drug Resistant EpilepsyEncephalitisAdolescentAdultAutoantibodiesAutoimmune Diseases of the Nervous SystemBiomarkersDiagnosis, DifferentialFemaleHashimoto DiseaseHumansIntracellular Signaling Peptides and ProteinsMagnetic Resonance SpectroscopyMaleMembrane ProteinsMetabolomicsAutoantibodiesBiomarkersCNTNAP2 protein, humanIntracellular Signaling Peptides and ProteinsLGI1 protein, humanMembrane ProteinsNerve Tissue ProteinsReceptors, N-Methyl-D-Aspartate

Identifiers

PMID39012808
PMCPMC11251473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.